Skip to main content
TARA
NASDAQ Life Sciences

Q3 Cash Drops to $143M as Net Loss Widens to $21.7M; STARBORN-1 Enrollment Slips to 1Q 2027

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$2.11
Mkt Cap
$125.873M
52W Low
$2.11
52W High
$7.82
52W Position info
0.0% above low
Off High info
73% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

TARA is trading near its 52-week low of $2.11 (0.0% above the low).

Summary

Protara burned through cash in Q3: unrestricted cash and investments fell to $143.1 million from $161.9 million at the end of Q2, and the net loss widened to $21.7 million ($0.35 per share) from $13.3 million a year earlier as R&D jumped to $16.8 million from $9.6 million. Management still says the balance funds operations into 2028. The bigger news is timing: enrollment in the registrational STARBORN-1 trial of TARA-002 in lymphatic malformations now completes early in 1Q 2027, with a rolling BLA submission in 2H 2027 — a slip from prior expectations. On the positive side, the BCG-Unresponsive cohort of ADVANCED-2 remains on track to finish enrollment by year-end 2026, and THRIVE-3 Phase 2b enrollment is complete with interim IV Choline Chloride data due by year-end 2026. Protara also agreed on November 4 to buy TARA-002 manufacturing assets from Novex Innovations for $8.75 million, bringing production in-house ahead of a potential launch. Watch the year-end 2026 ADVANCED-2 enrollment completion and THRIVE-3 interim results.

At the time of this announcement, TARA was trading at $2.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $125.9M. The 52-week trading range was $2.11 to $7.82. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

TARA - Latest Insights

TARA
Nov 06, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.11
Real-time Price: $2.27 info
Change: +$0.160 (+8%) info
Market Cap: $135.92M info
TARA
Aug 11, 2026, 8:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.27 info
Change: -$1.71 (-43%) info
Market Cap: $135.92M info
TARA
Aug 11, 2026, 8:05 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.27 info
Change: -$1.71 (-43%) info
Market Cap: $135.92M info
TARA
Aug 11, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $3.98
Real-time Price: $2.27 info
Change: -$1.71 (-43%) info
Market Cap: $135.92M info
TARA
Jul 01, 2026, 4:10 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $4.04
Real-time Price: $2.27 info
Change: -$1.77 (-44%) info
Market Cap: $135.92M info